Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.600
-0.140 (-3.74%)
At close: Dec 18, 2025, 4:00 PM EST
3.630
+0.030 (0.83%)
After-hours: Dec 18, 2025, 7:49 PM EST
Prime Medicine Stock Forecast
Stock Price Forecast
The 3 analysts that cover Prime Medicine stock have a consensus rating of "Buy" and an average price target of $6.42, which forecasts a 78.33% increase in the stock price over the next year. The lowest target is $4.25 and the highest is $9.00.
Price Target: $6.42 (+78.33%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 11, 2025.
Analyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $5 → $4.25 | Hold | Maintains | $5 → $4.25 | +18.06% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +150.00% | Nov 10, 2025 |
| Citigroup | Citigroup | Hold Maintains $1.5 → $4 | Hold | Maintains | $1.5 → $4 | +11.11% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +177.78% | Aug 8, 2025 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $10 → $1.5 | Strong Buy → Hold | Downgrades | $10 → $1.5 | -58.33% | May 27, 2025 |
Financial Forecast
Revenue This Year
6.32M
from 2.98M
Increased by 111.80%
Revenue Next Year
4.74M
from 6.32M
Decreased by -24.93%
EPS This Year
-1.32
from -1.65
EPS Next Year
-0.97
from -1.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 14.5M | 10.5M | ||||
| Avg | 6.3M | 4.7M | ||||
| Low | 3.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 385.6% | 66.2% | ||||
| Avg | 111.8% | -24.9% | ||||
| Low | 24.6% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.20 | -0.59 | ||||
| Avg | -1.32 | -0.97 | ||||
| Low | -1.38 | -1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.